REFERENCES
- Bercovici N., Givan A. L., Waugh M. G., Fisher J. L., Vernel-Pauillac F., Ernstoff M. S., Abastado J.P., Wallace P.K. Multiparameter precursor analysis of T-cell responses to antigen. J. Immunol. Meth. May 1, 2003; 276(1–2)5–17
- Bruns P. Die Heilwirkung des Erysipels auf Geschwulste. Beitr. Klin. Chir. 1887–1888; 3: 443
- Coley W. B. The treatment of malignant tumors by repeated inoculations of Erysipelas, with a report of ten original cases. Am. J. Med. Sci. 1893; 105: 487–511
- De Morgan C. Observations on cancer. Lancet 1874; i: 323–395
- Ernstoff M. S., Crocenzi T. S., Seigne J. D., Crosby N. A., Cole B. F., Fisher J. L., Uhlenhake J. C., Mellinger D., Foster C., Farnham C. J., Mackay K., Szczepiorkowski Z. M., Webber S. M., Schned A. R., Harris R. D., Barth R. J., Jr., Heaney J. A., Noelle R. J. Developing a rational tumor vaccine therapy for renal cell carcinoma: Immune yin and yang. Clin. Cancer Res. 2007; 13(2 Pt 2)733s–740s
- Ernstoff M. S., Nair S., Bahnson R. R., Miketic L. M., Banner B., Gooding W., Day R., Whiteside T., Hakala T., Kirkwood J. M. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 1990; 8: 1637–1649
- Givan A. L., Fisher J. L., Waugh M. G., Bercovici N., Wallace P. K. Use of cell-tracking dyes to determine proliferation precursor frequencies of antigen-specific T cells. Methods in Molecular Biology: Flow Cytometry Protocols2nd, T. S. Hawley, R. G. Hawley. Humana Press Inc, Totowa, NJ 2003; 109
- Givan A. L., Fisher J. L., Waugh M., Ernstoff M. S., Wallace P. K. A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J. Immunol. Meth. Nov 19, 1999/2000; 230(1–2)99–112, Erratum in: J. Immunol. Meth. Apr 3; 237(1–2):207.
- Hérin M., Lemoine C., Weynants P., Vessière F., Van Pel A., Knuth A., Devos R., Boon T. Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int. J. Cancer 1987; 39(3)390–396
- Horan P. K., Melnicoff M. J., Jensen B. D., Slezak S. E. Fluorescent cell labeling for in vivo and in vitm cell tracking. Meth. Cell Biol. 1990; 33: 469–490
- Keilholz U., Weber J., Finke J. H., Gabrilovich D. I., Kast W. M., Disis M. L., Kirkwood J. M., Scheibenbogen C., Schlom J., Maino V.C., Lyerly H. K., Lee P. P., Storkus W., Marincola F., Worobec A., Atkins M. B. Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the society for biological therapy. J. Immunother. 2002; 25(2)97–138
- Poon R. Y., Ohlsson-Wilhelm B. M., Bagwell C. B., Muirhead K. A. Use of PKH Membrane Intercalating Dyes to Monitor Cell Trafficking and Function. In Living Color: Flow Cytometry and Cell Sorting Protocols, R. A. Diamond, S. DeMaggio. Springer-Verlag, New York 2000; 302–352
- Schwaab T., Tretter C. P., Gibson J. J., Cole B. F., Schned A. R., Harris R., Fisher J. L., Crosby N., Stempkowski L. M., Heaney J. A., Ernstoff M. S. Tumor–related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF). Prostate 2006; 66(6)667–674
- Schwaab T., Tretter C. P., Gibson J. J., Cole B. F., Schned A. R., Harris R., Wallen E. M., Fisher J. L., Waugh M. G., Truman D., Stempkowski L. M., Crosby N. A., Heaney J. A., Ernstoff M. S. Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma. J. Urol. 2004; 171(3)1036–1042
- Wallace P. K., Tsang K. Y., Goldstein J., Correale P., Jarry T. M., Schlom J., Guyre P. M., Ersntoff M. S., Fanger M. W. Exogenous antigen targeted to FcgRI on myeloid cells is presented in association with MHC class I. J. Immunol. Meth. 2000; 248: 183–194
- Weidmann E., Logan T. F., Yasumura S., Kirkwood J. M., Trucco M., Whiteside T. L. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes. Cancer Res. 1993; 53: 4745–4749